Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.

@article{AttardoParrinello1987EffectsOA,
  title={Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis. Comparison with dichloromethylene diphosphonate.},
  author={Giuseppe Attardo-Parrinello and Gianpaolo Merlini and Franco Pavesi and Francesca Crema and Mauro Fiorentini and Edoardo Ascari},
  journal={Archives of internal medicine},
  year={1987},
  volume={147 9},
  pages={1629-33}
}
We have compared in an open trial the clinical and biochemical effects of a new aminodiphosphonate, aminohydroxybutylidene diphosphonate, with those of dichloromethylene diphosphonate, which has been proved effective. The patients presented extensive and symptomatic bone involvement from multiple myeloma, breast cancer, and other metastatic tumors. The treatment consisted of aminohydroxybutylidene diphosphonate, 2.5 mg/d intravenously for five days, or dichloromethylene diphosphonate, 300 mg/d… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

Weekly oral alendronate in mevalonate kinase deficiency

Orphanet journal of rare diseases • 2013
View 1 Excerpt

Similar Papers

Loading similar papers…